Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRF1 | P14222 | 15/20 | 0.53 |
| ▸ | UGCG | Q16739 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15571223 | 0.89 | PRF1 (0.48) | PRF1DRD2DRD4DRD3SRD5A1 | |
| SCHEMBL15570926 | 0.86 | DRD2 (0.52) | PRF1DRD2DRD4DRD3SRD5A1 | |
| SCHEMBL15571389 | 0.80 | PRF1 (0.53) | PRF1DRD2DRD4DRD3SRD5A1 | |
| SCHEMBL15570900 | 0.78 | PRF1 (0.54) | PRF1DRD2DRD4DRD3SRD5A1 | |
| SCHEMBL15571028 | 0.78 | PRF1 (0.51) | PRF1DRD2DRD4DRD3SRD5A1 | |
| SCHEMBL20924158 | 0.77 | PRF1 (0.57) | PRF1 | |
| SCHEMBL15570922 | 0.76 | PRF1 (0.56) | PRF1 | |
| SCHEMBL8980806 | 0.76 | SLC6A11 (0.54) | — | |
| SCHEMBL15572021 | 0.76 | DRD2 (0.49) | PRF1DRD2DRD4DRD3 | |
| SCHEMBL2015843 | 0.75 | PRF1 (0.64) | PRF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2888251-B1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INST (AU) | 2019-04-24 | — | — | EP | disclosed |
| EP-2888251-B1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INST (AU) | 2019-04-24 | — | — | EP | disclosed |
| US-9896443-B2 | Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-02-20 | — | — | US | disclosed |
| US-9896443-B2 | Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-02-20 | — | — | US | disclosed |
| US-20150218150-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-08-06 | — | — | US | disclosed |
| US-20150218150-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-08-06 | — | — | US | disclosed |
| US-20150218150-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-08-06 | — | — | US | disclosed |
| EP-2888251-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | Peter MacCallum Cancer Institute (AU) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014028968-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2014-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218150-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PRF1, GZMB, BAK1 | PRF1 1/4885UGCG 3126/4885DRD2 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.